India extends Synriam approval to P vivax malaria
This article was originally published in Scrip
Executive Summary
Ranbaxy Laboratories' Synriam (arterolane maleate 150mg plus piperaquine phosphate 750mg) has been approved in India for the treatment of uncomplicated Plasmodium vivax malaria in adults, in addition to its previous indication of P falciparum malaria.